Contact Us

OVM-200

Home
Blog Standard
Tag: OVM-200
Page 2
Company News March 4, 2024 Oxford Vacmedix Comments: 0

New opportunity for Oxford Vacmedix future clinical development through sale of Head of Clinical Operations, Mark Thomas’ company Clinicology Ltd.

FGK Clinical Research GmbH, announces the successful acquisition of Clinicology Ltd. This strategic move marks a significant milestone for both companies and benefits OVM Oxford, UK – 4th March 2024 Press Release – Sale of Clinicology Ltd. Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that Clinicology Ltd, the contract research organisation company owned by Mark Thomas, Head of Clinical Operations has been acquired by a Germ...
Read More
Company News November 28, 2023 Oxford Vacmedix Comments: 0

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing discussions with its largest shareholder DxVx for lead cancer vaccine OVM-200. If concluded the licensing deal will grant DxVx...
Read More
Company News May 26, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the need for invasive treatments such as chemotherapy and radiotherapy for some cancers in future. Watch Oxfo...
Read More
en_GBEnglish
en_GBEnglish